Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Evaluating the Effect of Omnaris Nasal Spray 200 Mcg QD and Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 Mcg BID and QVAR Inhalation Aerosol 40 Mcg BID vs Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma and Allergic Rhinitis

Next Previous
Trial Profile

A Study Evaluating the Effect of Omnaris Nasal Spray 200 Mcg QD and Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 Mcg BID and QVAR Inhalation Aerosol 40 Mcg BID vs Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma and Allergic Rhinitis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclesonide (Primary) ; Ciclesonide (Primary) ; Beclometasone; Beclometasone
  • Indications Allergic rhinitis; Asthma
  • Focus Adverse reactions

Most Recent Events

  • 07 Mar 2016 Status changed from recruiting to completed according to results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 06 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top